Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer

SIMPLE SUMMARY: ER+ breast cancer is the most diagnosed subtype and patient prognosis has improved in recent years thanks largely to the development of endocrine-targeting therapies including tamoxifen. Unfortunately, many tumors will recur as endocrine-therapy-resistant metastases. Therefore, in or...

Descripción completa

Detalles Bibliográficos
Autores principales: Zboril, Emily K., Grible, Jacqueline M., Boyd, David C., Hairr, Nicole S., Leftwich, Tess J., Esquivel, Madelyn F., Duong, Alex K., Turner, Scott A., Ferreira-Gonzalez, Andrea, Olex, Amy L., Sartorius, Carol A., Dozmorov, Mikhail G., Harrell, J. Chuck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296623/
https://www.ncbi.nlm.nih.gov/pubmed/37370789
http://dx.doi.org/10.3390/cancers15123179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296623/
https://www.ncbi.nlm.nih.gov/pubmed/37370789
http://dx.doi.org/10.3390/cancers15123179

Ejemplares similares